• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines

tetano

Editor, Senior Moderator
Front Immunol. 2018 Oct 9;9:2312. doi: 10.3389/fimmu.2018.02312. eCollection 2018.
[h=1]Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.[/h] Dong W[SUP]1,[/SUP][SUP]2[/SUP], Bhide Y[SUP]1[/SUP], Sicca F[SUP]1[/SUP], Meijerhof T[SUP]1[/SUP], Guilfoyle K[SUP]3[/SUP], Engelhardt OG[SUP]3[/SUP], Boon L[SUP]4[/SUP], de Haan CAM[SUP]5[/SUP], Carnell G[SUP]6[/SUP], Temperton N[SUP]6[/SUP], de Vries-Idema J[SUP]1[/SUP], Kelvin D[SUP]2,[/SUP][SUP]7[/SUP], Huckriede A[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Sequential infection with antigenically distinct influenza viruses induces cross-protective immune responses against heterologous virus strains in animal models. Here we investigated whether sequential immunization with antigenically distinct influenza vaccines can also provide cross-protection. To this end, we compared immune responses and protective potential against challenge with A(H1N1)pdm09 in mice infected sequentially with seasonal A(H1N1) virus followed by A(H3N2) virus or immunized sequentially with whole inactivated virus (WIV) or subunit (SU) vaccine derived from these viruses. Sequential infection provided solid cross-protection against A(H1N1)pdm09 infection while sequential vaccination with WIV, though not capable of preventing weight loss upon infection completely, protected the mice from reaching the humane endpoint. In contrast, sequential SU vaccination did not prevent rapid and extensive weight loss. Protection correlated with levels of cross-reactive but non-neutralizing antibodies of the IgG2a subclass, general increase of memory T cells and induction of influenza-specific CD4+ and CD8+ T cells. Adoptive serum transfer experiments revealed that despite lacking neutralizing activity, serum antibodies induced by sequential infection protected mice from weight loss and vigorous virus growth in the lungs upon A(H1N1)pdm09 virus challenge. Antibodies induced by WIV vaccination alleviated symptoms but could not control virus growth in the lung. Depletion of T cells prior to challenge revealed that CD8+ T cells, but not CD4+ T cells, contributed to cross-protection. These results imply that sequential immunization with WIV but not SU derived from antigenically distinct viruses could alleviate the severity of infection caused by a pandemic and may improve protection to unpredictable seasonal infection.


[h=4]KEYWORDS:[/h] antigenically distinct influenza virus strains; cross-protection; immune mechanism; non-neutralizing antibody; sequential vaccination

PMID: 30356772 PMCID: PMC6189474 DOI: 10.3389/fimmu.2018.02312
Free full text
 
Back
Top Bottom